共查询到19条相似文献，搜索用时 296 毫秒
1.
建立了高效液相色谱—串联质谱法（HPLC-MS/MS）检测鸡蛋中恩诺沙星、环丙沙星残留的方法。鸡蛋样品经1%乙酸乙腈提取、正己烷除脂, 用HPLC-MS/MS进行检测。恩诺沙星、环丙沙星在0.5~500 ng/mL浓度时线性关系良好（r≥0.999）;恩诺沙星回收率为87.7%~99.1%、环丙沙星的回收率为89.1%~101.4%, 检测限为0.5 μg/kg, 定量限为1.0 μg/kg。应用该方法初步研究了恩诺沙星及其代谢物环丙沙星在鸡蛋中的残留消除规律。结果表明, 给药后鸡蛋中恩诺沙星及其代谢物蓄积迅速, 停药8 d后痕量恩诺沙星代谢缓慢, 25 d后恩诺沙星代谢完全。 相似文献
2.
关于恩诺沙星及其代谢物残留检测的研究进展 总被引：1，自引：0，他引：1
本文综述了恩诺沙星及其代谢物在动物性食品中残留检测的研究进展。包括两方面的内容:恩诺沙星在动物性食品中的残留和休药期;国内外关于恩诺沙星及其代谢物环丙沙星残留的检测方法,如微生物法、酶联免疫法、高效液相色谱法、毛细管电泳法。 相似文献
3.
超高效液相法检测鸡蛋中四种氟喹诺酮类药物残留,样品经1%甲酸乙腈提取后,荧光检测器检测分析。结果表明,四种氟喹诺酮类药物的峰面积与浓度呈现良好的线性关系,相关系数R20.9999。在环丙沙星、恩诺沙星、沙拉沙星添加浓度为10、100、200μg/kg和达氟沙星添加浓度为2、20、40μg/kg的情况下,四种氟喹诺酮类药物的回收率为73.4%~99.1%,各药物批内、批间相对标准偏差均小于10%,适用于鸡蛋中氟喹诺酮类药物残留的检测。 相似文献
4.
利用胶体金标记的抗氟喹诺酮类单克隆抗体制备了氟喹诺酮类胶体金免疫检测试纸条。该试纸条对牛奶中恩诺沙星、沙拉沙星、双氟沙星、氧氟沙星、诺氟沙星、环丙沙星、培氟沙星、氟甲喹、达氟沙星检测限为20g／L。对依诺沙星、恶喹酸检测限为40g／L,检测时间5min,与三聚氰胺、磺胺类药物、氯霉素、大环内酯类药物、氨基糖苷类药物、四环素类药物在500g／L浓度时,不发生交叉反应。试纸条的检测结果与仪器检测结果一致,重复性较好,在4℃条件下可以保存12个月,所以该研究制备的氟喹诺酮类药物残留检测试纸条可用于牛奶中11种氟喹诺酮类药物残留。 相似文献
5.
利用胶体金标记的抗氟喹诺酮类单克隆抗体制备了氟喹诺酮类胶体金免疫检测试纸条。该试纸条对牛奶中恩诺沙星、沙拉沙星、双氟沙星、氧氟沙星、诺氟沙星、环丙沙星、培氟沙星、氟甲喹、达氟沙星检测检测限为20ug／L;对依诺沙星、恶喹酸检测检测限为40ug／L,检测检测时间5min：与三聚氰胺、磺胺类药物、氯霉素、大环内酯类药物、氨基糖苷类药物、四环素类药物在500μg／L浓度时,不发生交叉反应。试纸条的检测结果与仪器检测结果一致,重复性较好,在4℃条件下可以保存12个月,所以本研究制备的氟喹诺酮类药物残留检测试纸条可用于牛奶中11种氟喹诺酮类药物残留的检测。 相似文献
6.
7.
胶体金免疫层析法快速检测牛奶中氟喹诺酮类药物残留 总被引：1，自引：0，他引：1
利用胶体金标记的抗氟喹诺酮类单克隆抗体制备了氟喹诺酮类胶体金免疫检测试纸条.该试纸条对牛奶中恩诺沙星、沙拉沙星、双氟沙星、氧氟沙星、诺氟沙星、环丙沙星、培氟沙星、氟甲喹、达氟沙星检测,检测限为20μg/L;对依诺沙星、恶喹酸检测,检测限为40μg/L.检测时间为5min.与三聚氰胺、磺胺类药物、氯霉素、大环内酯类药物、氨基糖苷类药物、四环素类药物在500μg/L浓度时,不发生交叉反应.试纸条的检测结果与仪器检测结果一致,重复性较好,在4℃条件下可以保存12个月.本研究制备的氟喹诺酮类药物残留检测试纸条可用于牛奶中11种氟喹诺酮类药物残留的检测. 相似文献
8.
建立了鸡蛋中环丙沙星、达氟沙星、恩诺沙星和沙拉沙星4种氟喹诺酮类药物残留测定的超高效液相色谱方法。样品经磷酸盐缓冲液提取后,用正己烷脱脂,C18固相萃取柱净化,反相高效液相色谱分离,荧光检测器测定。本方法的检测限为环丙沙星、恩诺沙星和沙拉沙星5 μg/kg,达氟沙星1 μg/kg。环丙沙星、恩诺沙星和沙拉沙星在2~200 ng/mL、达氟沙星在0.4～40 ng/mL范围内呈线性相关,相关系数r大于0.9999。在空白鸡蛋中添加环丙沙星、恩诺沙星和沙拉沙星5~50 μg/kg、达氟沙星1～10 μg/kg,4种氟喹诺酮类药物的平均回收率为82.2～101.3％,批内变异系数0.8～5.9％之间(n＝6),批间变异系数在1.0～6.6％之间(n＝4)。结果表明,该法灵敏、准确、特异性强,适用于鸡蛋中氟喹诺酮类药物残留的测定。 相似文献
9.
为了建立一种同时测定牛奶中4种氟喹诺酮类药物(恩诺沙星、环丙沙星、沙拉沙星、二氟沙星)多残留高效液相色谱检测方法,将牛奶中的残留药物用磷酸-甲醇溶液重复提取2次,正己烷除去脂肪净化后浓缩,流动相溶解后用高效液相色谱-荧光检测器测定。结果表明,4种氟喹诺酮类药物在0.01~1.00μg/mL浓度范围内具有良好的线性关系(R=0.999 9),在0.01,0.05,0.10,0.50μg/mL和1.00μg/mL 5个浓度添加水平上,平均回收率为77%~93%,样品的批内和批间变异系数均值分别为5.29%和7.83%,定量限均为10 ng/mL。环丙沙星、恩诺沙星、沙拉沙星检测限均为5 ng/mL,二氟沙星检测限为8 ng/mL。本研究建立的检测方法简单、快速、灵敏度和回收率高,适用于牛奶中4种氟喹诺酮类药物残留检测。 相似文献
10.
恩诺沙星（Enrofloxacin，ENR）又名乙基环丙沙星，为第一个畜禽专用的氟喹诺酮类药物，1983年由德国拜耳公司首先研制成功，国内产品于1994年投放市场。该药广谱抗菌，对霉形体和革兰氏阴性菌效力强，对革兰氏阳性及厌氧菌效果稍弱；内服及肌肉注射吸收迅速，且在体内代谢为同样具有抗菌活性的环丙沙星，代谢物生成与消除缓慢、分布广泛，是养殖户治疗畜禽疾病的常用药之一。 相似文献
11.
Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs 总被引：6，自引：0，他引：6
Anadón A Martínez-Larrañaga MR Díaz MJ Fernández-Cruz ML Martínez MA Frejo MT Martínez M Iturbe J Tafur M 《American journal of veterinary research》1999,60(11):1377-1382
OBJECTIVES: To determine pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after a single i.v. and i.m. administration of enrofloxacin and tissue residues after serial daily i.m. administration of enrofloxacin in pigs. ANIMALS: 20 healthy male pigs. PROCEDURE: 8 pigs were used in a crossover design to investigate pharmacokinetics of enrofloxacin after a single i.v. and i.m. administration (2.5 mg/kg of body weight). Twelve pigs were used to study tissue residues; they were given daily doses of enrofloxacin (2.5 mg/kg, i.m. for 3 days). Plasma and tissue concentrations of enrofloxacin and ciprofloxacin were determined. Residues of enrofloxacin and ciprofloxacin were measured in fat, kidney, liver, and muscle. RESULTS: Mean (+/-SD) elimination half-life and mean residence time of enrofloxacin in plasma were 9.64+/-1.49 and 12.77+/-2.15 hours, respectively, after i.v. administration and 12.06+/-0.68 and 17.15+/-1.04 hours, respectively, after i.m. administration. Half-life at alpha phase of enrofloxacin was 0.23+/-0.05 and 1.94+/-0.70 hours for i.v. and i.m. administration, respectively. Maximal plasma concentration was 1.17 +/-0.23 microg/ml, and interval from injection until maximum concentration was 1.81+/-0.23 hours. Renal and hepatic concentrations of enrofloxacin (0.012 to 0.017 microg/g) persisted for 10 days; however, at that time, ciprofloxacin residues were not detected in other tissues. CONCLUSIONS AND CLINICAL RELEVANCE: Enrofloxacin administered i.m. at a dosage of 2.5 mg/kg for 3 successive days, with a withdrawal time of 10 days, resulted in a sum of concentrations of enrofloxacin and ciprofloxacin that were less than the European Union maximal residue limit of 30 ng/g in edible tissues. 相似文献
12.
M. Slana V. Pahor L. Cvitkovi
Mari
i
M. Sollner‐Dolenc 《Journal of veterinary pharmacology and therapeutics》2014,37(6):611-614
The metabolism and excretion of enrofloxacin were studied when applied as oral solution to chicken broilers for five consecutive days. Sixty 9‐day‐old broilers were isolated within an intensively rearing poultry farm during enrofloxacin therapy (15.5 mg/kg per day). The excreta of the isolated broilers were collected daily, 9 days after therapy termination, for 13 consecutive days, and analyzed for the presence of enrofloxacin and its metabolites [ciprofloxacin, desethylene‐enrofloxacin (DES‐EF) and desethylene‐ciprofloxacin (DES‐CF)]. Enrofloxacin was excreted predominantly in the form of the parent compound between days 1 and 13. Ciprofloxacin was detected in the excreta between days 1 and 6, whereas minor amounts of DES‐EF and DES‐CF were excreted only between days 1–7 and 1–6, respectively. In conclusion, the analysis of the excreta showed that approximately 74% of orally applied enrofloxacin was excreted as the parent compound, approximately 25% as the main metabolite ciprofloxacin, and approximately 1% as the minor metabolites desethylene‐enrofloxacin and desethylene‐ciprofloxacin. 相似文献
13.
Davis JL Foster DM Papich MG 《Journal of veterinary pharmacology and therapeutics》2007,30(6):564-571
The purpose of this study was to establish the pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in the plasma and interstitial fluid (ISF) following subcutaneous (s.c.) administration of enrofloxacin. Ultrafiltration probes were placed in the s.c. tissue, gluteal musculature, and pleural space of five calves. Each calf received 12.5 mg/kg of enrofloxacin. Plasma and ISF samples were collected for 48 h after drug administration and analyzed by high pressure liquid chromatography. Plasma protein binding of enrofloxacin and ciprofloxacin was measured using a microcentrifugation system. Tissue probes were well tolerated and reliably produced fluid from each site. The mean +/- SD plasma half-life was 6.8 +/- 1.2 and 7.3 +/- 1 h for enrofloxacin and ciprofloxacin, respectively. The combined (ciprofloxacin + enrofloxacin) peak plasma concentration (Cmax) was 1.52 microg/mL, and the combined area under the curve (AUC) was 25.33 microg/mL. The plasma free drug concentrations were 54% and 81% for enrofloxacin and ciprofloxacin, respectively, and free drug concentration in the tissue fluid was higher than in plasma. We concluded that Cmax/MIC and AUC/MIC ratios for free drug concentrations in plasma and ISF would meet suggested ratios for a targeted MIC of 0.06 microg/mL. 相似文献
14.
采用HPLC-DAD-MSn法对兔肌注恩诺沙星给药后血浆中恩诺沙星和代谢产物的紫外光谱和质谱裂解行为进行分析,获得各化合物的光谱和多级质谱信息。比较给药前后兔血浆的DAD检测色谱图,发现6个可能的代谢产物M1……M6。根据化合物结构和质谱裂解途径及标准品的色谱保留时间,确定M3为环丙沙星,并推测M5可能为加氧恩诺沙星;M4获得一级质谱数据和紫外光谱数据;M1、M2和M6仅得到紫外光谱数据。推测恩诺沙星在兔体内的主要代谢反应是脱乙基反应和氧化反应。 相似文献
15.
Lynette K. Cole Mark G. Papich† Kenneth W. Kwochka‡ rew Hillier Daniel D. Smeak§ Amy M. Lehman¶ 《Veterinary dermatology》2009,20(1):51-59
The purpose of this study was to measure the concentrations of enrofloxacin and its metabolite ciprofloxacin following intravenous administration of enrofloxacin in the plasma and ear tissue of dogs with chronic end-stage otitis undergoing a total ear canal ablation and lateral bulla osteotomy. The goals were to determine the relationship between the dose of enrofloxacin and the concentrations of enrofloxacin and ciprofloxacin, and determine appropriate doses of enrofloxacin for treatment of chronic otitis externa and media. Thirty dogs were randomized to an enrofloxacin-treatment group (5, 10, 15 or 20 mg kg−1 ) or control group (no enrofloxacin). After surgical removal, ear tissue samples (skin, vertical ear canal, horizontal ear canal, middle ear) and a blood sample were collected. Concentrations of enrofloxacin and ciprofloxacin in the plasma and ear tissue were measured by high performance liquid chromatography. Repeated measures models were applied to log-transformed data to assess dosing trends and Pearson correlations were calculated to assess concentration associations. Ear tissue concentrations of enrofloxacin and ciprofloxacin were significantly ( P < 0.05) higher than plasma concentrations. Each 5 mg kg−1 increase in the dose of enrofloxacin resulted in a 72% and 37% increase in enrofloxacin and ciprofloxacin concentrations, respectively. For bacteria with an minimal inhibitory concentration of 0.12–0.15 or less, 0.19–0.24, 0.31–0.39 and 0.51–0.64 µg mL−1 , enrofloxacin should be dosed at 5, 10, 15 and 20 mg kg−1 , respectively. Treatment with enrofloxacin would not be recommended for a bacterial organism intermediate or resistant in susceptibility to enrofloxacin since appropriate levels of enrofloxacin would not be attained. 相似文献
16.
鸡蛋中氟喹诺酮类药物残留量检测方法研究 总被引：4，自引：1，他引：3
建立一种可同时检测鸡蛋中四种氟喹诺酮类药物(环丙沙星、达氟沙星、恩诺沙星和沙拉沙星)残留的高效液相色谱-荧光检测法。结果表明,四种氟喹诺酮类药物中环丙沙星、恩诺沙星、沙拉沙星在2~500 ng/mL范围内峰面积与浓度呈良好的线性关系,R2均大于0.9999;达氟沙星在0.4~100 ng/mL范围内峰面积与浓度呈良好的线性关系,R2大于0.9999。环丙沙星、恩诺沙星、沙拉沙星的定量限为10μg/kg,达氟沙星的定量限为2μg/kg。环丙沙星、恩诺沙星、沙拉沙星在10~200μg/kg的浓度添加水平上,其回收率为70%~100%;达氟沙星在2~40μg/kg的浓度添加水平上,其回收率为70%~100%,批内、批间的相对标准偏差均小于10%。 相似文献
17.
18.
Hawkins Boothe Guinn Aucoin & Ngyuen 《Journal of veterinary pharmacology and therapeutics》1998,21(1):18-23
The purpose of this study was to determine the concentration of enrofloxacin and its active metabolite, ciprofloxacin, in alveolar macrophages (AM) and epithelial lining fluid (ELF) of the lungs in comparison to plasma concentrations in healthy dogs. Eleven dogs were given a single oral dose (5 mg/kg) of enrofloxacin. Four hours later, plasma and bronchoalveolar lavage (BAL) fluid were collected. Cells were separated from the BAL fluid and lysed for determination of drug concentrations within AM. Supernatant was used to determine concentrations of drugs in ELF. Drug assays were performed by high-performance liquid chromatography.
The concentration of enrofloxacin (mean ± SD) was 0.33 ± 0.14 μg/mL in plasma, 3.34 ± 2.4 μg/mL in AM and 4.79 ± 5.0 μg/mL in ELF. The concentration of ciprofloxacin was 0.42 ± 0.26 μg/mL in plasma, 1.15 ± 1.03 μg/mL in AM and 0.26 ± 0.26 μg/mL in ELF. Mean concentrations of both drugs in AM were greater than in plasma (AM to plasma ratio, 10.3 for enrofloxacin and 4.7 for ciprofloxacin). Mean concentrations of enrofloxacin, but not ciprofloxacin, in ELF were greater than in plasma (ELF to plasma ratio, 13.5 for enrofloxacin and 0.52 for ciprofloxacin). Enrofloxacin concentrations in AM and ELF largely exceeded the MICs of the major bacterial pathogens and surpassed by about two times the breakpoint MIC of that drug, and ciprofloxacin concentrations in AM surpassed the MIC of many susceptible organisms. These results suggest that sufficient antimicrobial activity is present in AM and ELF of dogs following oral administration of enrofloxacin to be effective in the treatment of lower respiratory tract infections involving susceptible organisms. 相似文献
The concentration of enrofloxacin (mean ± SD) was 0.33 ± 0.14 μg/mL in plasma, 3.34 ± 2.4 μg/mL in AM and 4.79 ± 5.0 μg/mL in ELF. The concentration of ciprofloxacin was 0.42 ± 0.26 μg/mL in plasma, 1.15 ± 1.03 μg/mL in AM and 0.26 ± 0.26 μg/mL in ELF. Mean concentrations of both drugs in AM were greater than in plasma (AM to plasma ratio, 10.3 for enrofloxacin and 4.7 for ciprofloxacin). Mean concentrations of enrofloxacin, but not ciprofloxacin, in ELF were greater than in plasma (ELF to plasma ratio, 13.5 for enrofloxacin and 0.52 for ciprofloxacin). Enrofloxacin concentrations in AM and ELF largely exceeded the MICs of the major bacterial pathogens and surpassed by about two times the breakpoint MIC of that drug, and ciprofloxacin concentrations in AM surpassed the MIC of many susceptible organisms. These results suggest that sufficient antimicrobial activity is present in AM and ELF of dogs following oral administration of enrofloxacin to be effective in the treatment of lower respiratory tract infections involving susceptible organisms. 相似文献
19.
为了解吉林省某地鸡源性沙门氏菌的感染及耐药情况,对该地7个肉鸡场150份病鸡组织样品进行细菌分离,并进行了血凝试验、致病性试验和药敏试验。分离得到26株沙门氏菌,经血凝鉴定有19株呈阳性,其中5株呈强阳性并均能使雏鸡致死。药敏试验结果显示,该5株沙门氏菌对头孢噻肟较为敏感;对氨苄西林、替米考星、林可霉素、阿奇霉素和头孢拉定表现出极高的耐药性,耐药率高达100%;诺氟沙星、恩诺沙星、环丙沙星、强力霉素和氯霉素5种临床用药与痢菌净不具有协同或累加作用。试验结果表明,沙门氏菌是危害该地肉鸡养殖场的主要病原菌之一,且耐药性十分严重。 相似文献